Rigel Q4 net product sales $65.4M record; full year net income $367M, includes $245.9M tax benefit

RIGEL PHARMACEUTICALS INC

Q4 2025 net product sales $65.4M (+41% YoY); TAVALISSE $45.6M (+47%), GAVRETO $10.2M (+27%), REZLIDHIA $9.6M (+29%).
Full year 2025 net product sales $232M (+60% YoY); total revenue $294.3M.
Q4 net income $268.1M ($14.72 basic EPS) includes $245.9M non-cash deferred tax benefit; FY net income $367M.
2026 guidance: total revenue $275-290M, net product sales $255-265M, expects positive net income.
Cash $155.0M at Dec 31, 2025 vs $77.3M at Dec 31, 2024; R289 dose expansion enrollment on track for H2 2026 RP2D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.